The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
A UK team sequenced the exomes of 16 fetuses and their parents, delivering a molecular diagnosis for 13.
In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.
Noninvasive prenatal screening for trisomies and sub-chromosomal alterations uncovered a fragile site expansion and related deletion present in mothers but not fetuses.
Three national organizations focused on prenatal, perinatal, and maternal-fetal care issued a consensus position statement related to genome-wide sequencing for fetal diagnosis.
The new funding comes from life sciences investment firm Perceptive Advisors. Home Care Assistance CEO Lily Sarafan has also joined Counsyl's board.
Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.
In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.